SecSonar.com

Evommune, Inc. (EVMN)

Evommune, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Evommune, Inc. (EVMN) is a Biotechnology company based in US with a market capitalization of $324.9M. Revenue grew 85.7% year-over-year and free cash flow was negative at -$76.7M. This page tracks EVMN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 45 employees · IPO Nov 6, 2025

Valuation

Valuation & price

$22.92 · as of May 17, 2026 · -27.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

1.58

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$31.57$22.27$12.96Nov 25Mar 26Jul 26Nov 6, 25$20.23Nov 7, 25$18.41Nov 10, 25$19.32Nov 12, 25$19.52Nov 13, 25$18.22Nov 14, 25$18.30Nov 18, 25$20.19Nov 19, 25$19.29Nov 20, 25$18.71Nov 24, 25$19.38Nov 25, 25$18.75Nov 26, 25$19.41Dec 1, 25$20.91Dec 2, 25$21.05Dec 4, 25$21.93Dec 5, 25$21.90Dec 8, 25$18.44Dec 10, 25$19.61Dec 11, 25$19.69Dec 12, 25$18.01Dec 16, 25$15.86Dec 17, 25$15.92Dec 18, 25$15.01Dec 22, 25$17.11Dec 23, 25$17.91Dec 24, 25$17.59Dec 29, 25$18.00Dec 30, 25$17.52Jan 2, 26$17.31Jan 5, 26$15.37Jan 6, 26$16.08Jan 8, 26$18.23Jan 9, 26$20.13Jan 12, 26$21.14Jan 14, 26$21.25Jan 15, 26$19.60Jan 16, 26$16.80Jan 21, 26$18.85Jan 22, 26$18.89Jan 23, 26$18.87Jan 27, 26$19.60Jan 28, 26$20.49Jan 30, 26$18.10Feb 2, 26$19.23Feb 3, 26$18.48Feb 5, 26$16.66Feb 6, 26$17.31Feb 9, 26$16.99Feb 11, 26$28.46Feb 12, 26$27.88Feb 13, 26$31.57Feb 18, 26$31.10Feb 19, 26$28.73Feb 20, 26$28.31Feb 24, 26$27.88Feb 25, 26$29.86Feb 27, 26$26.00Mar 2, 26$25.61Mar 3, 26$23.88Mar 5, 26$25.09Mar 6, 26$26.50Mar 9, 26$24.61Mar 11, 26$23.40Mar 12, 26$22.98Mar 13, 26$21.99Mar 17, 26$25.03Mar 18, 26$24.09Mar 20, 26$23.33Mar 23, 26$23.45Mar 24, 26$21.02Mar 26, 26$23.67Mar 27, 26$22.18Mar 30, 26$22.00Apr 1, 26$22.42Apr 2, 26$23.72Apr 6, 26$24.58Apr 8, 26$27.13Apr 9, 26$28.65Apr 10, 26$25.51Apr 14, 26$26.63Apr 15, 26$26.94Apr 17, 26$27.45Apr 20, 26$27.97Apr 21, 26$28.07Apr 23, 26$25.84Apr 24, 26$25.38Apr 27, 26$25.00Apr 29, 26$23.85Apr 30, 26$23.80May 1, 26$24.50May 5, 26$24.16May 6, 26$23.83May 7, 26$22.50May 11, 26$23.21May 12, 26$22.69May 14, 26$22.72May 15, 26$22.92May 18, 26$21.89May 20, 26$22.28May 21, 26$23.55May 22, 26$22.87May 27, 26$23.34May 28, 26$23.33May 29, 26$23.23Jun 2, 26$19.82Jun 3, 26$19.73Jun 4, 26$20.69Jun 8, 26$20.19Jun 9, 26$20.49Jun 11, 26$20.69Jun 12, 26$19.83Jun 15, 26$20.84Jun 17, 26$20.65Jun 18, 26$21.36Jun 22, 26$22.55Jun 24, 26$23.56Jun 25, 26$24.13Jun 26, 26$25.18Jun 30, 26$13.29Jul 2, 26$12.96
$12.8252-week range$31.57
Loading valuation history…

Fundamentals

Key fundamentals

$324.9M

Market cap

85.7%

Revenue growth (YoY)

100.0%

Gross margin

-$76.7M

Free cash flow (USD)

-$147.1M

Net debt

Net cash position

4.8%

Share dilution

1/4

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2023 → 2025

FY 2023$5.0MFY 2024$7.0MFY 2025$13.0M
$5M$13M

Free cash flow by year

2023 → 2025

FY 2023$-30.1MFY 2024$-58.3MFY 2025$-76.7M
-$30.1M-$76.7M

Gross margin by year

2023 → 2025

FY 202380.0%FY 202481.6%FY 2025100.0%
80.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

8

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventPhase 2b Trial ResultsJun 29, 2026Filing
  • Insider sellInsider Sell $33K · 10b5-1 PlanPatel Jeegar Pravinkumar · Chief Scientific Officer · $33.5KJun 24, 2026Filing
  • Insider sellInsider Sell $453K · 10b5-1 PlanDrew Janice Suzann · Chief of Dev. Operations · $452.6KJun 24, 2026Filing
  • Insider sellInsider Sell $169K · 10b5-1 PlanPena Luis C. · Director, President & CEO · $168.9KJun 24, 2026Filing
  • Insider sellInsider Sell $382K · 10b5-1 PlanPena Luis C. · Director, President & CEO · $381.7KJun 3, 2026Filing
  • Insider sellInsider Sell $379K · 10b5-1 PlanPatel Jeegar Pravinkumar · Chief Scientific Officer · $379.5KJun 3, 2026Filing
  • Insider sellInsider Sell $123K · 10b5-1 PlanCohen David E · Director · $123.1KJun 3, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 2, 2026Filing
  • Insider sellInsider Sell $415K · 10b5-1 PlanCarver Kyle · Chief Financial Officer · $415.1KJun 1, 2026Filing
  • Insider sellInsider Sell $325K · 10b5-1 PlanMoss Gregory S. · Chief Business & Legal Officer · $324.7KJun 1, 2026Filing

Questions

Frequently asked questions

What is Evommune, Inc.'s market cap?

Evommune, Inc. (EVMN) has a market capitalization of $324.9M.

What is EVMN's P/E ratio?

A meaningful P/E ratio is not available for EVMN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is EVMN's price-to-book (P/B) ratio?

EVMN trades at 1.58 times book value per share.

Are insiders buying EVMN stock?

SEC Form 4 filings show no open-market insider buys at Evommune, Inc. in the last 90 days (8 sells).

Same arena

Related companies in Biotechnology

BCYC

Bicycle Therapeutics plc

$325.5M

OABI

OmniAb, Inc.

$323.4M

SLN

Silence Therapeutics plc

$320.4M

EDIT

Editas Medicine, Inc.

$331.4M

FATE

Fate Therapeutics, Inc.

$317M

CMPX

Compass Therapeutics, Inc.

$334M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.